AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34419529 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month home-based mobile CR programme with telemonitoring and coaching based on motivational interviewing (n=79)
Number of subjects: 179
Study 34419529 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=100)
Number of subjects: 179
Study 32493215 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel or ticagrelor for carriers of CYP2C19*2 loss‐of‐function allele
Number of subjects: 1500
Study 32493215 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel for non-carriers of CYP2C19*2 loss‐of‐function allele
Number of subjects: 1500
Study 35780106 — intervention group
Group type: EXPERIMENTAL
Intervention: SAYGo airway topical anesthesia and superior laryngeal nerve (SLN) block combined with transtracheal injection (TTI)
Number of subjects: 66
Study 35780106 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthetic regimen (Group C)
Number of subjects: 66
Study 35780106 — intervention group
Group type: EXPERIMENTAL
Intervention: SAYGo airway topical anesthesia and SLN block combined with TTI
Number of subjects: 66
Study 33939193 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin (AMX) plus metronidazole (MTZ)
Number of subjects: 62
Study 33939193 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth mechanical debridement and decontamination with chlorhexidine
Number of subjects: 62
Study 34103619 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-enhanced radiomics model
Number of subjects: 292
Study 34103619 — intervention group
Group type: COMPARATOR
Intervention: Clinical prediction model
Number of subjects: 292
Study 34515623 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-problematic video game use
Number of subjects: 3939
Study 34515623 — intervention group
Group type: EXPERIMENTAL
Intervention: Problematic video game use
Number of subjects: 3939
Study 33381805 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rewarming (at >0.5°C/h)
Number of subjects: 100
Study 33381805 — intervention group
Group type: COMPARATOR
Intervention: Slow rewarming (at ≤0.5°C/h)
Number of subjects: 100
Study 33381805 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rewarming
Number of subjects: 100
Study 33381805 — intervention group
Group type: COMPARATOR
Intervention: Slow rewarming
Number of subjects: 100
Study 35148020 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA stimulation
Number of subjects: 45
Study 35148020 — intervention group
Group type: COMPARATOR
Intervention: VIM stimulation
Number of subjects: 45
Study 34322547 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-inhaler triple therapy (12.5 μg glycopyrronium, 12 μg formoterol, 250 μg fluticasone)
Number of subjects: 396
Study 34322547 — intervention group
Group type: COMPARATOR
Intervention: Open-triple therapy (50 μg glycopyrronium co-administered with 12 μg formoterol and 250 μg fluticasone)
Number of subjects: 396
Study 34357480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oro-buccal administered cannabidiol-dominant anti-inflammatory formulation (MDCNB-02)
Number of subjects: 16
Study 34357480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32992570 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 Hz saccadic eye movement (SEM)
Number of subjects: 17
Study 32992570 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz saccadic eye movement (SEM)
Number of subjects: 17
Study 32992570 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Hz saccadic eye movement (SEM)
Number of subjects: 17
Study 35669747 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (segmented simulation curriculum)
Number of subjects: 55
Study 35669747 — intervention group
Group type: COMPARATOR
Intervention: Control group (single case running and debriefing)
Number of subjects: 55
Study 34501213 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability physiotherapy
Number of subjects: 135
Study 34501213 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 135
Study 34501213 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study 33036790 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene, letrozole, or gonadotropins with intrauterine insemination for women with UI; Clomiphene or letrozole with regular intercourse for women with PCOS.
Number of subjects: 1650
Study 33036790 — intervention group
Group type: COMPARATOR
Intervention: Weight gain of ≥3 kg in women with PCOS.
Number of subjects: 1650
Study 35266085 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 units of BTX around the eye and normal saline around the mouth (group A)
Number of subjects: 60
Study 35266085 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 units of BTX around both the eye and the mouth (group B)
Number of subjects: 60
Study 33010998 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid with cartoon pictures (intervention)
Number of subjects: 110
Study 33010998 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 110
Study 35759282 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Tobacco Care Management (TTCM)
Number of subjects: 1409
Study 35759282 — intervention group
Group type: COMPARATOR
Intervention: Community-based quitline (QL)
Number of subjects: 1409
Study 32798174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil intervention before ERCP
Number of subjects: 90
Study 616121449 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized reminder letters and telephone calls
Number of subjects: 250
Study 616121449 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no reminder calls or letters)
Number of subjects: 250
Study 33320726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant 7 (40 Gy‐5)
Number of subjects: 90
Study 33320726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant 10 (40 Gy‐8)
Number of subjects: 90
Study 33320726 — intervention group
Group type: COMPARATOR
Intervention: Check variety 'Avadh'
Number of subjects: 90
Study 33963477 — intervention group
Group type: EXPERIMENTAL
Intervention: InThistoGether (ITG) text messaging-based HIV prevention program
Number of subjects: 202
Study 33963477 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control group promoting general health
Number of subjects: 202
Study 32542578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring groups
Number of subjects: 676
Study 32542578 — intervention group
Group type: COMPARATOR
Intervention: Control condition (pairs not embedded in a group)
Number of subjects: 676
Study 34543751 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic manual rotation
Number of subjects: 160
Study 34543751 — intervention group
Group type: COMPARATOR
Intervention: Sham rotation
Number of subjects: 160
Study 33515757 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 0
Study 33515757 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Daily Injections (MDI)
Number of subjects: 0
Study 33515757 — intervention group
Group type: COMPARATOR
Intervention: Prestudy U-500R
Number of subjects: 0
Study 33515757 — intervention group
Group type: COMPARATOR
Intervention: Non-U-500R
Number of subjects: 0
Study 33549502 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (postoperative pupillary diameter reduction)
Number of subjects: 109
Study 33549502 — intervention group
Group type: COMPARATOR
Intervention: Women (postoperative pupillary diameter reduction)
Number of subjects: 109
Study 33549502 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (photopic postoperative pupil reduction)
Number of subjects: 109
Study 33549502 — intervention group
Group type: COMPARATOR
Intervention: Women (photopic postoperative pupil reduction)
Number of subjects: 109
Study 33549502 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of photopic pupillary changes in women with age
Number of subjects: 109
Study 33549502 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of mesopic pupillary changes in men with age
Number of subjects: 109
Study 33591620 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN from the adventitia of the renal artery plus unilateral laparoscopic adrenalectomy
Number of subjects: 60
Study 33591620 — intervention group
Group type: COMPARATOR
Intervention: Adrenalectomy alone (control group)
Number of subjects: 60
Study 33131222 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) intervention supported by CQI mentors in seven primary care clinics
Number of subjects: 0
Study 33131222 — intervention group
Group type: EXPERIMENTAL
Intervention: CQI intervention
Number of subjects: 0
Study 33798308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger-separated moxibustion, 30 min each time, once every other day, three times a week for 4 weeks
Number of subjects: 62
Study 33798308 — intervention group
Group type: COMPARATOR
Intervention: Normal diet and moderate exercise
Number of subjects: 62
Study 616039576 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye gel (FC formulated as eye gel)
Number of subjects: 16
Study 616039576 — intervention group
Group type: COMPARATOR
Intervention: Eye drops (FC formulated as eye drops)
Number of subjects: 16
Study 35405005 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive applied on dry dentin
Number of subjects: 45
Study 35405005 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive applied on moist dentin
Number of subjects: 45
Study 33766150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus olanzapine (n = 64)
Number of subjects: 269
Study 33766150 — intervention group
Group type: COMPARATOR
Intervention: Sertraline plus placebo (n = 62)
Number of subjects: 269
Study 32812840 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuttering treatment integrated with evidence-based parenting support (EBPS) for children with eADHD (eADHDintegrated)
Number of subjects: 76
Study 32812840 — intervention group
Group type: COMPARATOR
Intervention: Stuttering treatment only for children with eADHD (eADHDstandard)
Number of subjects: 76
Study 32812840 — intervention group
Group type: COMPARATOR
Intervention: Stuttering treatment only for children without eADHD (No-eADHDstandard)
Number of subjects: 76
Study 32812840 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuttering treatment integrated with EBPS for children with eADHD (eADHDintegrated)
Number of subjects: 76
Study 35373603 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (TA)
Number of subjects: 74
Study 35373603 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 74
Study 33388462 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum depression symptoms assessment using the Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 3174
Study 33388462 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parity (≥3 previous deliveries)
Number of subjects: 3174
Study 33388462 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal and paternal schooling, presence of husband or partner, support from child's father and family during pregnancy
Number of subjects: 3174
Study 34697250 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining with visual biofeedback
Number of subjects: 24
Study 34697250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback on running biomechanics)
Number of subjects: 24
Study 33370517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondamaging retinal laser therapy (NRT)
Number of subjects: 12
Study 33370517 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 12
Study 33370517 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 12
Study 32631324 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH-HF plus usual care
Number of subjects: 216
Study 32631324 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216
Study 35982464 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-99677
Number of subjects: 37
Study 35982464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 32183608 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-containing prenatal multiple micronutrient (MMN) supplement (300 μg of iodine)
Number of subjects: 875
Study 32183608 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (FeFol) supplement
Number of subjects: 875
Study 35191982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor in preadmission aspirin and/or clopidogrel group
Number of subjects: 4018
Study 35191982 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel in preadmission aspirin and/or clopidogrel group
Number of subjects: 4018
Study 35191982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor in no preadmission aspirin or clopidogrel group
Number of subjects: 4018
Study 35191982 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel in no preadmission aspirin or clopidogrel group
Number of subjects: 4018
Study 33370510 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous ketorolac
Number of subjects: 165
Study 33370510 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous ketorolac
Number of subjects: 165
Study 33370510 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg intravenous ketorolac
Number of subjects: 165
Study 33370510 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue analgesic (0.1 mg/kg intravenous morphine sulfate)
Number of subjects: 165
Study 33370510 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 165
Study 35228846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume HIIT (n = 16)
Number of subjects: 35
Study 35228846 — intervention group
Group type: COMPARATOR
Intervention: MICT (n = 19)
Number of subjects: 35
Study 36122874 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 114
Study 36122874 — intervention group
Group type: COMPARATOR
Intervention: No IOL implantation (contact lens [CL])
Number of subjects: 114
Study 36122874 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with glaucoma
Number of subjects: 114
Study 36122874 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eyes
Number of subjects: 114
Study 32942346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5-3 mg/d
Number of subjects: 0
Study 32942346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/d
Number of subjects: 0
Study 32942346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/d
Number of subjects: 0
Study 32942346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine overall (1.5-3 mg/d)
Number of subjects: 0
Study 35306502 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐DL+TAU
Number of subjects: 148
Study 32050833 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Preservation (ARP) using socket grafting with a particulate bone allograft and socket sealing with a nonabsorbable membrane (dPTFE)
Number of subjects: 53
Study 32050833 — intervention group
Group type: COMPARATOR
Intervention: Tooth extraction only (EXT)
Number of subjects: 53
Study 32050833 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Preservation (ARP)
Number of subjects: 53
Study 32050833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 34244378 — intervention group
Group type: EXPERIMENTAL
Intervention: Paratroopers
Number of subjects: 196336
Study 34244378 — intervention group
Group type: COMPARATOR
Intervention: Non-paratroopers
Number of subjects: 196336
Study 33430891 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (120 mg IV once daily on days 1, 2, and 3) plus standard of care
Number of subjects: 72
Study 33430891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline IV once daily on days 1, 2, and 3) plus standard of care
Number of subjects: 72
Study 34967844 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa (3.6 mg goserelin or 3.75 mg leuprorelin injected subcutaneously once every 28 days)
Number of subjects: 330
Study 34967844 — intervention group
Group type: COMPARATOR
Intervention: Control (chemotherapy without GnRHa)
Number of subjects: 330
Study 34967844 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa group
Number of subjects: 330
Study 34967844 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 330
Study 34967844 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa group (in patients younger than 35 years)
Number of subjects: 330
Study 34967844 — intervention group
Group type: COMPARATOR
Intervention: Control group (in patients younger than 35 years)
Number of subjects: 330
Study 33931353 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparison (PC) intervention
Number of subjects: 4589
Study 33931353 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4589
Study 32118304 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically managed (SX) horses
Number of subjects: 98
Study 32118304 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgically managed (non-SX) horses
Number of subjects: 98
Study 33588478 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylazine (0.1 mg/kg)
Number of subjects: 10
Study 33588478 — intervention group
Group type: EXPERIMENTAL
Intervention: Detomidine (0.03 mg/kg)
Number of subjects: 10
Study 32480409 — intervention group
Group type: COMPARATOR
Intervention: Goserelin acetate plus 0 grams of testosterone gel (placebo)
Number of subjects: 177
Study 32480409 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus 1.25 grams of testosterone gel
Number of subjects: 177
Study 32480409 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus 2.5 grams of testosterone gel
Number of subjects: 177
Study 32480409 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus 5 grams of testosterone gel
Number of subjects: 177
Study 32480409 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus 10 grams of testosterone gel
Number of subjects: 177
Study 36300485 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reading
Number of subjects: 120
Study 36300485 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral reading
Number of subjects: 120
Study 36300485 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 34517431 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach: approaching important goals that they have been avoiding
Number of subjects: 66
Study 34517431 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward: increasing pleasant, rewarding behaviors
Number of subjects: 66
Study 34517431 — intervention group
Group type: COMPARATOR
Intervention: Control: monitoring only
Number of subjects: 66
Study 35210331 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 1764
Study 35210331 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 1764
Study 32690738 — intervention group
Group type: EXPERIMENTAL
Intervention: STARWAVe clinical prediction rule (CPR)
Number of subjects: 252
Study 32690738 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter illness duration (3 days)
Number of subjects: 252
Study 32690738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vomiting present
Number of subjects: 252
Study 32690738 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeze present
Number of subjects: 252
Study 35524405 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab (100 mg and 300 mg doses)
Number of subjects: 895
Study 35524405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 895
Study 35524405 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 895
Study 34779394 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study 34779394 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 0
Study 34779394 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 0
Study 34779394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33080951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying intervention training for middle managers
Number of subjects: 142
Study 36100210 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC) training using the role-play method
Number of subjects: 2
Study 36100210 — intervention group
Group type: COMPARATOR
Intervention: Routine methods (control group)
Number of subjects: 2
Study 33187890 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A
Number of subjects: 46
Study 33187890 — intervention group
Group type: COMPARATOR
Intervention: Extended-release tolterodine
Number of subjects: 46
Study 33063932 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured 10-week exercise program (progressive aerobic and resistance exercise)
Number of subjects: 43
Study 33063932 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 43
Study 33063932 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured 10-week exercise program
Number of subjects: 43
Study 33487155 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg/day (n=73)
Number of subjects: 109
Study 33487155 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (n=36)
Number of subjects: 109
Study 34267085 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT with Internet support group
Number of subjects: 403
Study 34267085 — intervention group
Group type: COMPARATOR
Intervention: cCBT without Internet support group
Number of subjects: 403
Study 34267085 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT
Number of subjects: 403
Study 33084584 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and mobile health-based physical activity intervention with Fitbit usage
Number of subjects: 17
Study 33084584 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline daily steps
Number of subjects: 17
Study 36428089 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 564
Study 36428089 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary Behaviour (SB) intervention
Number of subjects: 564
Study 36428089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PA and SB groups
Number of subjects: 564
Study 36428089 — intervention group
Group type: EXPERIMENTAL
Intervention: PA group
Number of subjects: 564